Kris, M. G.; Johnson, B. E.; Kwiatkowski, D. J.; Iafrate, A. J.; Bunn, P. A. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). J. Clin. Oncol., 2011, 29(18_suppl), CRA7506-CRA7506.
Tsao, M.-S. Hainaut, Pierre, BOURREDJEM, Abderrahmane, LACE-Bio pooled analysis of the prognostic and predictive value of KRAS mutation in completely resected non-small cell lung cancer (NSCLC). Ann Oncol., 2010, 21(viii63)
Yasuda, H.; Sng, N.J.; Yeo, W.L.; Figueiredopontes, L.L.; Kobayashi, S.; Costa, D.B. sensitivity of EGFR exon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR. Cancer Res, 2012, 72(8) (Suppl.), 23.
Liu, L.; Hong, S.; Zhang, V.; Gilmer, T. Identification of molecular determinants of response to gsk1120212b, a potent and selective mek inhibitor, as a single agent and in combination in ras/raf mutant non-small cell lung carcinoma cells. Cancer Res., 2011, 71(8) (Suppl.), 4394.